Expand ALLO Menu
ALLO MENU

ALLO Latest Press Releases

-- May 28, 2026 --

Allogene Therapeutics Announces Planned CEO Succession Globe Newswire 5:02 PM

-- May 26, 2026 --

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences Globe Newswire 8:31 AM

-- May 13, 2026 --

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update Globe Newswire 4:02 PM

-- May 6, 2026 --

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update Globe Newswire 8:30 AM

-- April 21, 2026 --

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia Globe Newswire 8:30 AM

-- April 20, 2026 --

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 Globe Newswire 8:30 AM

-- April 16, 2026 --

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock Globe Newswire 4:01 PM

-- April 15, 2026 --

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases Globe Newswire 8:30 AM

-- April 14, 2026 --

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock Globe Newswire 9:50 PM

-- April 13, 2026 --

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock Globe Newswire 4:01 PM
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma Business Wire 8:00 AM
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL Globe Newswire 7:30 AM

-- April 10, 2026 --

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 Globe Newswire 4:02 PM

-- March 12, 2026 --

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update Globe Newswire 4:02 PM

-- March 2, 2026 --

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes